There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Outlook Therapeutics (OTLK – Research Report) and Exagen (XGN – Research Report) with bullish sentiments.
Outlook Therapeutics (OTLK)
In a report released yesterday, Julian Harrison from BTIG reiterated a Buy rating on Outlook Therapeutics, with a price target of $7.00. The company’s shares closed last Monday at $1.20.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of
Currently, the analyst consensus on Outlook Therapeutics is a Strong Buy with an average price target of $6.06, representing a 427.0% upside. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $5.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Exagen (XGN)
In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on Exagen, with a price target of $5.00. The company’s shares closed last Monday at $2.91, close to its 52-week low of $2.04.
According to TipRanks.com, Massaro has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Exagen is a Moderate Buy with an average price target of $5.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on OTLK:
- OTLK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2023 and Provides Corporate Update
- Outlook Therapeutics® to Present at the H.C. Wainwright BioConnect Investor Conference
- Outlook Therapeutics management to meet virtually with BTIG
- Guggenheim starts Outlook Therapeutics at Buy on Lytenava opportunity
